Amgen continues M&A flurry with $3.7bn deal

Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics | Deal includes acquisition of Tavneos (avacopan) | Spate of acquisitions follows increased competition.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

GSK bets $2.1bn on Boston-based biopharma company

1 June 2022 GlaxoSmithKline has agreed to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston and focusing on developing vaccines.

Big Pharma

Amgen asks Fed Circ to rehear $1.1bn Juno patent suit

16 November 2021 Amgen and two research centres have thrown their support behind Bristol Myers Squibb subsidiary Juno Therapeutics to help restore a $1.1 billion patent judgment against Kite Pharma that was overturned by the US Court of Appeals for the Federal Circuit.

Americas

Amgen seals $28m deal for biotech

13 December 2022 Two rivals withdrew from acquisition process| Agreement provides access to blockbuster medicines | Janssen Global Services | Sanofi.

More on this story

Big Pharma

GSK bets $2.1bn on Boston-based biopharma company

1 June 2022 GlaxoSmithKline has agreed to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston and focusing on developing vaccines.

Big Pharma

Amgen asks Fed Circ to rehear $1.1bn Juno patent suit

Americas

Amgen seals $28m deal for biotech

13 December 2022 Two rivals withdrew from acquisition process| Agreement provides access to blockbuster medicines | Janssen Global Services | Sanofi.

More on this story

Big Pharma

GSK bets $2.1bn on Boston-based biopharma company

1 June 2022 GlaxoSmithKline has agreed to acquire Affinivax, a clinical-stage biopharmaceutical company based in Cambridge, Boston and focusing on developing vaccines.

Big Pharma

Amgen asks Fed Circ to rehear $1.1bn Juno patent suit

Americas

Amgen seals $28m deal for biotech

13 December 2022 Two rivals withdrew from acquisition process| Agreement provides access to blockbuster medicines | Janssen Global Services | Sanofi.